Algae Biosciences Corporation

May 04, 2011 18:39 ET

Algae Biosciences Corporation Receives Final TSX Venture Exchange Bulletin Relating to Qualifying Transaction

CALGARY, ALBERTA--(Marketwire - May 4, 2011) -

NOT FOR DISTRIBUTION TO THE UNITED STATES WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES

Algae Biosciences Corporation – TSX-V: ABV (formerly Triwood Capital Corp.) (TSX VENTURE:TRD.H) (the "Corporation") is pleased to announce that the TSX Venture Exchange (the "Exchange") has issued its final bulletin (the "Final Bulletin") in connection with the completion of the Corporation's "Qualifying Transaction" (as such term is defined in the policies of the Exchange) (the "Qualifying Transaction"), which occurred on April 13, 2011 and which is disclosed in the Corporation's press release on April 15, 2011. As set out in the Final Bulletin, trading in the common shares of the Corporation will be reinstated on Thursday, May 6, 2011, under the new trading symbol "ABV".

Additional information regarding the Qualifying Transaction can be viewed on SEDAR under the Corporation's company profile at www.sedar.com.

Cautionary Statements

The common shares of the Corporation have not been and will not be registered under the United States Securities Act of 1933, as amended and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Not for distribution to U.S. Newswire Services or for dissemination in the United States of America. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • Algae Biosciences Corporation
    Andrew Ayers
    Chief Executive Officer
    (928) 240-1060